Abnova
Taipei, Taiwan· Est.
Abnova provides integrated antibody and cellular reagent solutions to accelerate biomedical research.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Abnova provides integrated antibody and cellular reagent solutions to accelerate biomedical research.
OncologyImmunologyInfectious Diseases
Technology Platform
Proprietary NanoAb™ ultra‑small antibody fragments combined with automated RNA synthesis (RNAutomation™) and rapid CAR‑T cell line generation (nanoCAR‑T).
Opportunities
Expanding mRNA and CAR‑T services can capture growing demand in gene‑therapy and immuno‑oncology research, while NanoAb™ differentiation offers premium pricing potential.
Risk Factors
Intense competition from large reagent distributors and the need for continuous assay development may pressure margins and market share.
Competitive Landscape
Competes with Thermo Fisher, Abcam, Bio‑Legend, and other antibody providers; differentiation hinges on NanoAb™ technology and integrated cell/RNA service platforms.